Orchestra BioMed Holdings (OBIO) Cash from Investing Activities Growth (1y) (2023 - 2026)
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Cash from Investing Activities Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -242.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -242.51% |
| Mar 31, 2026 | -20.62% |
| Dec 31, 2025 | -371.94% |
| Sep 30, 2025 | -7,027.11% |
| Jun 30, 2025 | 56.91% |
| Mar 31, 2025 | 121.79% |
| Dec 31, 2024 | -111.32% |
| Sep 30, 2024 | -95.70% |
| Jun 30, 2024 | 28.41% |
| Mar 31, 2024 | 113.46% |
| Dec 31, 2023 | 152.31% |
| Sep 30, 2023 | 5,879.91% |
| Jun 30, 2023 | 1,812.66% |
| Mar 31, 2023 | -92,514.89% |